Advertisement
Advertisement

KLRS

KLRS logo

Kalaris Therapeutics, Inc. Common Stock

8.85
USD
Sponsored
-0.35
-3.80%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

8.84

-0.01
-0.17%

KLRS Earnings Reports

Positive Surprise Ratio

KLRS beat 10 of 19 last estimates.

53%

Next Report

Date of Next Report
Mar 05, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.54
Implied change from Q3 25 (Revenue/ EPS)
--
/
-15.63%
Implied change from Q4 24 (Revenue/ EPS)
--
/
--

Kalaris Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, KLRS reported earnings of -0.64 USD per share (EPS) for Q3 25, beating the estimate of -0.66 USD, resulting in a 3.89% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.54 USD, with revenue projected to reach -- USD, implying an decrease of -15.63% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Kalaris Therapeutics, Inc. Common Stock reported EPS of -$0.64, beating estimates by 3.89%, and revenue of $0.00, 0% as expectations.
The stock price moved down -2.17%, changed from $5.07 before the earnings release to $4.96 the day after.
The next earning report is scheduled for Mar 05, 2026.
Based on 8 analysts, Kalaris Therapeutics, Inc. Common Stock is expected to report EPS of -$0.54 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement